In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".

Authors	Min Huang, Ralph P Insinga, Thomas Burke, Ying Zhang, Gilberto de Lima Lopes
Journal	Lung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 146 Pg. 385-386 (08 2020) ISSN: 1872-8332 [Electronic] Ireland
PMID	32593484 (Publication Type: Letter, Comment)
Chemical References	Antibodies, Monoclonal, Humanized B7-H1 Antigen pembrolizumab
Topics	Antibodies, Monoclonal, Humanized B7-H1 Antigen Carcinoma, Non-Small-Cell Lung (drug therapy) Cost-Benefit Analysis Humans Lung Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!